Pharmaron Beijing Co., Ltd. (HKG:3759)

Pharmaron Beijing Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,302	1,690	5,919	1,497	3,544	2,942
Short-Term Investments	675.45	257.27	179.36	613.24	1,080	-
Trading Asset Securities	860.93	1,120	621.98	745.36	1,555	910.01
Cash & Short-Term Investments	2,838	3,068	6,720	2,856	6,178	3,852
Cash Growth	0.67%	-54.35%	135.30%	-53.77%	60.37%	-17.03%
Accounts Receivable	2,984	2,871	2,636	2,214	1,424	1,210
Other Receivables	81.64	126.89	80.98	71.16	92.43	33.38
Receivables	3,066	2,998	2,717	2,286	1,516	1,249
Inventory	1,305	1,117	1,013	1,041	680.04	281.62
Other Current Assets	383.96	425.67	423.68	352.82	269.05	157.76
Total Current Assets	7,593	7,608	10,874	6,536	8,644	5,540
Property, Plant & Equipment	11,324	10,798	10,062	8,464	5,811	3,799
Long-Term Investments	1,180	883.04	1,005	1,008	762.67	401.7
Goodwill	2,985	2,761	2,781	2,688	2,096	1,166
Other Intangible Assets	872.83	791	789.06	802.53	692.94	566.08
Long-Term Deferred Tax Assets	229.17	192.68	153.22	58.79	15.6	8.44
Long-Term Deferred Charges	644.39	678.5	520.47	496.38	171.6	234.27
Other Long-Term Assets	348.82	191.98	267.09	438.91	195.99	193.05
Total Assets	25,197	23,927	26,477	20,493	18,389	11,909
Accounts Payable	527.83	477.09	412.22	406.35	315.53	191.5
Accrued Expenses	820.77	853.93	805.65	784.92	626.21	472.44
Short-Term Debt	1,002	764.97	577.07	662.77	421.76	377.27
Current Portion of Long-Term Debt	331.16	282.34	150.34	74.94	60.54	8.88
Current Portion of Leases	137.06	149.51	185.32	164.03	95.29	83.92
Current Income Taxes Payable	89.29	160.08	184.55	145.87	81.34	27.62
Current Unearned Revenue	1,071	834.86	740.87	832.14	679.62	473.29
Other Current Liabilities	998.66	701.23	598.47	841.4	701.7	346.87
Total Current Liabilities	4,978	4,224	3,654	3,912	2,982	1,982
Long-Term Debt	4,209	4,377	8,200	4,454	4,423	394.81
Long-Term Leases	401.19	401.31	585.2	760.51	284.34	186.61
Long-Term Unearned Revenue	415.08	409.98	391.71	152.38	149.44	158.13
Long-Term Deferred Tax Liabilities	324.61	291.87	290.04	261.01	173.3	106.91
Other Long-Term Liabilities	-	-	117.58	112.09	81.56	146.81
Total Liabilities	10,328	9,705	13,239	9,653	8,094	2,975
Common Stock	1,778	1,778	1,787	1,191	794.18	794.39
Additional Paid-In Capital	4,919	5,008	5,222	5,254	6,008	6,028
Retained Earnings	7,606	7,257	5,818	4,574	3,554	2,131
Treasury Stock	-304.89	-416.27	-463.45	-668.04	-301.83	-45.47
Comprehensive Income & Other	268.3	-7.76	193.72	197.26	74.15	-38.22
Total Common Equity	14,266	13,619	12,557	10,549	10,129	8,870
Minority Interest	603.1	603.54	681.25	291.25	166.07	63.42
Shareholders' Equity	14,869	14,223	13,238	10,840	10,295	8,934
Total Liabilities & Equity	25,197	23,927	26,477	20,493	18,389	11,909
Total Debt	6,081	5,975	9,698	6,117	5,285	1,051
Net Cash (Debt)	-3,243	-2,908	-2,977	-3,260	893.04	2,801
Net Cash Growth	-	-	-	-	-68.12%	-22.27%
Net Cash Per Share	-1.84	-1.64	-1.68	-1.84	0.49	1.57
Filing Date Shares Outstanding	1,771	1,766	1,787	1,787	1,787	1,787
Total Common Shares Outstanding	1,771	1,766	1,787	1,787	1,787	1,787
Working Capital	2,615	3,384	7,220	2,624	5,662	3,559
Book Value Per Share	8.06	7.71	7.03	5.90	5.67	4.96
Tangible Book Value	10,409	10,068	8,987	7,058	7,340	7,138
Tangible Book Value Per Share	5.88	5.70	5.03	3.95	4.11	3.99
Buildings	5,262	4,921	3,971	3,347	2,473	1,673
Machinery	6,613	6,274	5,149	4,265	2,919	2,194
Construction In Progress	2,610	2,254	2,633	1,671	1,374	820.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.